413 related articles for article (PubMed ID: 30619849)
1. Heparan Sulfate as a Therapeutic Target in Tauopathies: Insights From Zebrafish.
Alavi Naini SM; Soussi-Yanicostas N
Front Cell Dev Biol; 2018; 6():163. PubMed ID: 30619849
[TBL] [Abstract][Full Text] [Related]
2. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
3. The Sulfation Code of Tauopathies: Heparan Sulfate Proteoglycans in the Prion Like Spread of Tau Pathology.
Mah D; Zhao J; Liu X; Zhang F; Liu J; Wang L; Linhardt R; Wang C
Front Mol Biosci; 2021; 8():671458. PubMed ID: 34095227
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms.
Hosokawa M; Masuda-Suzukake M; Shitara H; Shimozawa A; Suzuki G; Kondo H; Nonaka T; Campbell W; Arai T; Hasegawa M
Brain; 2022 Mar; 145(1):349-361. PubMed ID: 34515757
[TBL] [Abstract][Full Text] [Related]
5. [Neuroprotective treatment of tauopathies].
Respondek G; Krey L; Huber M; Pflugrad H; Wegner F; Höglinger GU
Nervenarzt; 2021 Dec; 92(12):1227-1238. PubMed ID: 34652482
[TBL] [Abstract][Full Text] [Related]
6. The Role of Tau Proteoforms in Health and Disease.
Waheed Z; Choudhary J; Jatala FH; Fatimah ; Noor A; Zerr I; Zafar S
Mol Neurobiol; 2023 Sep; 60(9):5155-5166. PubMed ID: 37266762
[TBL] [Abstract][Full Text] [Related]
7. Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies.
Morderer D; Wren MC; Liu F; Kouri N; Maistrenko A; Khalil B; Pobitzer N; Salemi M; Phinney BS; Dickson DW; Murray ME; Rossoll W
bioRxiv; 2024 Mar; ():. PubMed ID: 38585836
[TBL] [Abstract][Full Text] [Related]
8. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy.
Karimi N; Bayram Çatak F; Arslan E; Saghazadeh A; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt B):109445. PubMed ID: 36410182
[TBL] [Abstract][Full Text] [Related]
9. Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy.
Alavi Naini SM; Yanicostas C; Hassan-Abdi R; Blondeel S; Bennis M; Weiss RJ; Tor Y; Esko JD; Soussi-Yanicostas N
Transl Neurodegener; 2018; 7():6. PubMed ID: 29568517
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
11. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
[TBL] [Abstract][Full Text] [Related]
12. Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau
Stopschinski BE; Holmes BB; Miller GM; Manon VA; Vaquer-Alicea J; Prueitt WL; Hsieh-Wilson LC; Diamond MI
J Biol Chem; 2018 Jul; 293(27):10826-10840. PubMed ID: 29752409
[TBL] [Abstract][Full Text] [Related]
13. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.
Wagshal D; Sankaranarayanan S; Guss V; Hall T; Berisha F; Lobach I; Karydas A; Voltarelli L; Scherling C; Heuer H; Tartaglia MC; Miller Z; Coppola G; Ahlijanian M; Soares H; Kramer JH; Rabinovici GD; Rosen HJ; Miller BL; Meredith J; Boxer AL
J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):244-50. PubMed ID: 24899730
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
15. Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies.
Wang R; Lu KP; Zhou XZ
J Neurochem; 2023 Sep; 166(6):904-914. PubMed ID: 37638382
[TBL] [Abstract][Full Text] [Related]
16. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification.
Tarutani A; Miyata H; Nonaka T; Hasegawa K; Yoshida M; Saito Y; Murayama S; Robinson AC; Mann DMA; Tomita T; Hasegawa M
Brain; 2021 Sep; 144(8):2333-2348. PubMed ID: 33693528
[TBL] [Abstract][Full Text] [Related]
17. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
[TBL] [Abstract][Full Text] [Related]
18. The Unifying Hypothesis of Alzheimer's Disease: Heparan Sulfate Proteoglycans/Glycosaminoglycans Are Key as First Hypothesized Over 30 Years Ago.
Snow AD; Cummings JA; Lake T
Front Aging Neurosci; 2021; 13():710683. PubMed ID: 34671250
[TBL] [Abstract][Full Text] [Related]
19. Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy.
Tanaka H; Martinez-Valbuena I; Forrest SL; Couto B; Reyes NG; Morales-Rivero A; Lee S; Li J; Karakani AM; Tang-Wai DF; Tator C; Khadadadi M; Sadia N; Tartaglia MC; Lang AE; Kovacs GG
Brain; 2024 Apr; 147(4):1399-1411. PubMed ID: 37972275
[TBL] [Abstract][Full Text] [Related]
20. Genetic Disorders with Tau Pathology: A Review of the Literature and Report of Two Patients with Tauopathy and Positive Family Histories.
Tacik P; Sanchez-Contreras M; Rademakers R; Dickson DW; Wszolek ZK
Neurodegener Dis; 2016; 16(1-2):12-21. PubMed ID: 26550830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
